List of Angiotensin-receptor blocker (ARB) trials for COVID-19:
- Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection. Intervention: Losartan 12.5mg bid, can be increased based on SBP.
- Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease. Intervention: Valsartan titrated based on BP, maximum of 160mg bid.
- COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED). Intervention: Losartan, 25 mg po QD X 5-14 days "depending on availability."
- Study of Open Label Losartan in COVID-19. Intervention: Losartan 25mg qd, escalated to 50mg od.
- Losartan for Patients With COVID-19 Requiring Hospitalization. Intervention: Losartan 50mg od.
- Losartan for Patients With COVID-19 Not Requiring Hospitalization. Intervention: Losartan 25mg od.
- Telmisartan for Treatment of COVID-19 Patients. Intervention: Telmisartan 80mg bid.
- Results: Preliminary results
- Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19) (COVERAGE). Intervention: Telmisartan 20mg od.
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY). Intervention: ARB, dose/medication not specified.
- CLARITY 2.0. Intervention: ARB, dose/medication unknown, plus CCR2-inhibitor, DMX-200.
- Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia. Intervention: Losartan 25mg bid.
- Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN). Intervention: Losartan 50mg od.
- Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT). Intervention: Candesartan 4mg od, titrated up based on BP.
- Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients. Intervention: Telmisartan 40mg od.
- Host Response Mediators in Coronavirus (COVID-19) Infection (ARBS CORONA I). Intervention: observational study of existing ACEi/ARB users.
- Host response mediators in Coronavirus (COVID-19) infection - Is there a protective effect of ARBs on outcomes of Coronavirus infection? (ARBs CORONA II). Intervention: Losartan 25mg, then 24 hours later 50mg, then 24 hours later 100mg.
- The McGill RAAS-COVID-19 Randomized Controlled Trial (RAAS-COVID). Intervention: observational study of existing ACEi/ARB users. Will suspend or hold ACEi/ARB.
- Telmisartan in Respiratory Failure Due to COVID-19 (STAR-COVID). Intervention: Telmisartan 40mg od.
- Evaluation of the effects of Losartan in patients with corona virus disease 2019. Intervention: Losartan 25mg bid.
- The COVID-RASi Trial (COVID-19). Intervention: ACEi or ARB of choice (unspecified).
- Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS (COVIDANCE). Intervention: Losartan 50mg od, Spironolactone 25mg od.
- Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial (INTENSE-COV). Intervention: Lopinavir/ritonavir + telmisartan. Telmisartan 40mg od for 10 days.
ACE inhibitor trials:
- Ramipril for the Treatment of COVID-19 (RAMIC). Intervention: Ramipril 2.5 od.
- Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID) (CAPTOCOVID). Intervention: captopril 25mg od.
- Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2). Intervention: captopril 25mg alongside "aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization."
Other trials of renin-angiotensin modulation for COVID-19:
- Treatment of Angiotensin Peptide (1-7) for COVID-19
- Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO)
- Angiotensin 1-7 in the Therapy of Covid19
- TXA COVID-19 Clinical Trial
- RAS and Coagulopathy in COVID19
- Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients
- Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients (COVA)
- RAS and Coagulopathy in COVID19. Trial of AT1R agonist TRV027.
- Safety and Efficacy of C21 in Subjects With COVID-19. Intervention: AT2R agonist C21, 100mg bid.
- Results: "14 of 51 patients (27%) on a twice-daily dose of the drug (n=51) plus standard of care required oxygen therapy at the end of the treatment period vs. 22 of 55 patients (45%) in the control arm. That corresponds to a 40% relative risk reduction, an effect, the company said, that was “statistically significant (p=0.057) at the 10% level as predefined in the statistical analysis plan." - Press release on C21 results.
- Updated results: "At the end of the trial, about a week after the last dose of C21, the effect was even more pronounced, with only one patient in the C21 group still needing oxygen supplementation compared to 11 patients in the placebo group - a reduction by >90% (p<0.002)." - Press release on updated C21 results.